Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT5B | P51692 | 4/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | ASPH | Q12797 | 1/20 | 0.39 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22096013 | 0.92 | STAT5B (0.59) | STAT5BALDH1A1LMNATP53KDM4E | |
| SCHEMBL22096006 | 0.89 | STAT5B (0.77) | STAT5BALDH1A1LMNATP53KDM4E | |
| SCHEMBL22096032 | 0.88 | STAT5B (0.78) | STAT5BALDH1A1HDAC1HDAC6KDM4E | |
| SCHEMBL22096012 | 0.79 | STAT5B (0.83) | STAT5BALDH1A1 | |
| SCHEMBL22096004 | 0.78 | STAT5B (0.82) | STAT5BALDH1A1LMNATHRB | |
| SCHEMBL22096021 | 0.76 | STAT5B (0.82) | STAT5BALDH1A1LMNATP53L3MBTL1 | |
| SCHEMBL22096035 | 0.76 | STAT5B (0.72) | STAT5BALDH1A1LMNATHRB | |
| SCHEMBL22096030 | 0.76 | STAT5B (0.82) | STAT5BALDH1A1HDAC1HDAC6L3MBTL1 | |
| SCHEMBL22096039 | 0.75 | STAT5B (0.77) | STAT5BALDH1A1HDAC1HDAC6 | |
| SCHEMBL22096011 | 0.75 | STAT5B (0.88) | STAT5BALDH1A1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10683286-B2 | Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer | FREIE UNIVERSITAET BERLIN (DE) | 2020-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10683286-B2 | Furazan-3-carboxylic acid derivatives and use thereof in treatment of cancer | FLT3, MCL1, MYD88 | STAT5B 59/4885ALDH1A1 92/4885LMNA 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.